| Literature DB >> 33089917 |
Nicole J Edwards1, Charles Hwang1, Simone Marini1, Chase A Pagani1, Philip J Spreadborough2, Cassie J Rowe2, Pauline Yu1, Annie Mei1, Noelle Visser1, Shuli Li1, Geoffrey E Hespe1, Amanda K Huber1, Amy L Strong1, Miriam A Shelef3, Jason S Knight4, Thomas A Davis2, Benjamin Levi1,5.
Abstract
Ischemia reperfusion (IR) injury results in devastating skeletal muscle fibrosis. Here, we recapitulate this injury with a mouse model of hindlimb IR injury which leads to skeletal muscle fibrosis. Injury resulted in extensive immune infiltration with robust neutrophil extracellular trap (NET) formation in the skeletal muscle, however, direct targeting of NETs via the peptidylarginine deiminase 4 (PAD4) mechanism was insufficient to reduce muscle fibrosis. Circulating levels of IL-10 and TNFα were significantly elevated post injury, indicating toll-like receptor (TLR) signaling may be involved in muscle injury. Administration of hydroxychloroquine (HCQ), a small molecule inhibitor of TLR7/8/9, following injury reduced NET formation, IL-10, and TNFα levels and ultimately mitigated muscle fibrosis and improved myofiber regeneration following IR injury. HCQ treatment decreased fibroadipogenic progenitor cell proliferation and partially inhibited ERK1/2 phosphorylation in the injured tissue, suggesting it may act through a combination of TLR7/8/9 and ERK signaling mechanisms. We demonstrate that treatment with FDA-approved HCQ leads to decreased muscle fibrosis and increased myofiber regeneration following IR injury, suggesting short-term HCQ treatment may be a viable treatment to prevent muscle fibrosis in ischemia reperfusion and traumatic extremity injury.Entities:
Keywords: extracellular signal-regulated kinases (ERK) 1/2; hydroxychloroquine; inflammation; muscle fibrosis
Year: 2020 PMID: 33089917 PMCID: PMC8054227 DOI: 10.1096/fj.202000994RR
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191